A complete clinical reference on myopia progression — how fast is too fast, axial length benchmarks by age, the key studies, and when progression crosses the threshold for treatment. For clinicians and parents.
Myopia progresses when the eyeball continues to grow too long — a process called axial elongation. Every millimetre of additional axial length increases structural risk. Myopia is not just a refractive problem; it is a structural one. The primary clinical question is not "what is the prescription?" but "how fast is the eye growing, and where will it end up at age 18?"
Key principle: Axial length — not diopter prescription — determines long-term risk. Two children with −3.00D prescriptions can have very different axial lengths, and therefore very different risk profiles. An eye at 25.5mm with −3D carries far more structural risk than an eye at 23.5mm with −3D.
The following ranges are drawn from Tideman et al. 2018 (European cohort, n=5,766) and He et al. 2015 (East Asian cohort). East Asian children typically have axial lengths 0.3–0.5mm longer than age-matched European-descent children.
| Age | European/Mixed (typical) | East Asian (typical) | High risk threshold |
|---|---|---|---|
| 6 years | 22.0–22.8 mm | 22.3–23.1 mm | >23.5 mm |
| 7 years | 22.2–23.0 mm | 22.5–23.3 mm | >23.8 mm |
| 8 years | 22.5–23.3 mm | 22.8–23.6 mm | >24.0 mm |
| 9 years | 22.7–23.5 mm | 23.0–23.8 mm | >24.3 mm |
| 10 years | 23.0–23.8 mm | 23.3–24.1 mm | >24.6 mm |
| 11 years | 23.1–24.0 mm | 23.4–24.3 mm | >24.8 mm |
| 12 years | 23.3–24.2 mm | 23.6–24.5 mm | >25.0 mm |
| 13 years | 23.4–24.3 mm | 23.7–24.6 mm | >25.2 mm |
| 14 years | 23.5–24.4 mm | 23.8–24.7 mm | >25.4 mm |
| 16 years | 23.6–24.6 mm | 23.9–24.9 mm | >25.6 mm |
Sources: Tideman JWL et al. JAMA Ophthalmol 2018. He M et al. Ophthalmology 2015 (Shenzhen Myopia Study). High risk threshold = approximately 95th percentile for age.
| Age group | Normal growth rate | Fast (consider treatment) | Dangerous (treat now) |
|---|---|---|---|
| 6–8 years | 0.10–0.15 mm/yr | >0.20 mm/yr | >0.30 mm/yr |
| 9–12 years | 0.15–0.20 mm/yr | >0.25 mm/yr | >0.35 mm/yr |
| 13–16 years | 0.10–0.15 mm/yr | >0.20 mm/yr | >0.30 mm/yr |
Tideman et al. 2018 (JAMA Ophthalmology) showed that age of myopia onset is the strongest single predictor of final axial length at age 18. A child who becomes myopic at age 6 has, on average, 9–10 years of axial elongation before stabilisation. A child who becomes myopic at age 13 has only 4–5 years. Earlier onset = more total elongation = greater structural risk at adulthood, regardless of the rate of annual progression.
This is why the IMI 2025 consensus shifted the treatment trigger from "fast progressors" to "treat at diagnosis" in children under 10. Waiting for progression to accelerate before treating is the wrong framework for early-onset cases.
Tideman et al. 2016 showed that eyes above 26mm axial length have approximately 5× the risk of retinal detachment, ~3× the risk of glaucoma, and ~40× the risk of myopic maculopathy compared to emmetropic eyes. This makes 26mm a critical clinical boundary — not because risk jumps suddenly at this point, but because it represents the level at which structural complications become clinically significant at a population level.
Eyes projected to reach 26mm by age 18 without treatment should be prioritised for intervention regardless of current prescription.
Effective progression monitoring requires:
Clinical tip: A child moving from the 70th to the 85th percentile over 12 months is more concerning than a child stable at the 90th percentile. Percentile rank trend matters as much as absolute position.
Enter age + axial length. See growth percentile, projected AL at 18, and treatment impact — in under 30 seconds. Free, no login.
Open Myopia Calculator →No signup · No credit card · Under 30 seconds
Sources: Tideman JWL et al. JAMA Ophthalmol 2016;134:1355–1363 · Tideman JWL et al. Acta Ophthalmologica 2018;96:301–309 · He M et al. Ophthalmology 2015;133:768–775 · IMI 2025 Digest (Tahhan N et al.) · Flitcroft DI. Prog Retin Eye Res 2012;31:622–660